Regulus appoints new vice president of clinical development

Regulus Therapeutics, Inc., a biopharmaceutical company, announced Tuesday the appointment of Michael Huang as vice president of clinical development.

Huang, an experienced drug developer, will be responsible for leading the company's global clinical operations and medical affairs and will serve as a key member of the executive leadership team.

"Over the last two and a half years, Regulus has executed well on our 'Clinical Map Initiative' goals and we've advanced our lead microRNA therapeutic programs into important stages of clinical development," Paul Grint, president and CEO of Regulus, said. "RG-101 is being tested in Phase II, RG-012 is being tested in Phase I, and RG-125 is expected to enter the clinic by the end of 2015. To continue to strengthen our clinical capabilities, we are pleased to welcome Mike to Regulus. His expertise in advancing investigational drugs through both early and late-stage development will greatly enhance our ability to bring microRNA therapeutics to patients in need."

Most recently, Huang served as vice president of Clinical Development at Auspex Pharmaceuticals, Inc.

"I am excited to join Paul and the Regulus team, who are so enthusiastic and committed to creating a new class of high-impact medicines based on microRNAs," Huang said. "At Regulus, we are uniquely positioned to leverage our oligonucleotide drug discovery and development expertise to treat a wide variety of serious diseases and I feel confident in our ability to make meaningful impacts on patients' lives."